Truist Financial Increases Insmed (NASDAQ:INSM) Price Target to $108.00
Insmed (NASDAQ:INSM – Free Report) had its price objective hoisted by Truist Financial from $105.00 to $108.00 in a research note released on Friday,Benzinga reports. Truist Financial currently has a buy rating on the biopharmaceutical company’s stock. Several other research firms also recently issued reports on INSM. Wells Fargo & Company boosted their price objective […]
Insmed (NASDAQ:INSM – Free Report) had its price objective hoisted by Truist Financial from $105.00 to $108.00 in a research note released on Friday,Benzinga reports. Truist Financial currently has a buy rating on the biopharmaceutical company’s stock. Several other research firms also recently issued reports on INSM. Wells Fargo & Company boosted their price objective […]
